English Українська
  • Головна
  • Корисні посилання
  • Про журнал
  • Авторам
  • Редакційна колегія

    •
    Стаття
    Світ Медицини та Біології / №2(92), 2025 / АНТИФОСФОЛІПІДНИЙ ПАТЕРН ЯК СКЛАДОВА ПАТОГЕНЕЗУ ІНФАРКТУ МІОКАРДА
    Л. В. Бурдейна, М. С. Назарова, Н. В. Кузьмінова, С. Е. Лозінський, В. М. Хоменко, Л. В. Швець, І. І. Князькова

    АНТИФОСФОЛІПІДНИЙ ПАТЕРН ЯК СКЛАДОВА ПАТОГЕНЕЗУ ІНФАРКТУ МІОКАРДА

    Про автора: Л. В. Бурдейна, М. С. Назарова, Н. В. Кузьмінова, С. Е. Лозінський, В. М. Хоменко, Л. В. Швець, І. І. Князькова
    Рубрика ОГЛЯДИ ЛІТЕРАТУРИ
    Тип статті Наукова стаття
    Анотація Проведено системний огляд міжнародної літератури, використовуючи платформу Pubmed. Метою дослідження було отримати інформацію про роль антифосфоліпідного синдрому в патогенезі інфаркту міокарда. У молодих пацієнтів гострий інфаркт міокарду може бути першим проявом атифосфоліпідного синдрому. Молоді пацієнти до 50 років без додаткових факторів ризику серцево-судинних захворювань або атеросклерозу коронарних артерій з рецидивуючими серцево-судинними подіями, зокрема інфарктом міокарду, повинні проходити обстеження на антифосфоліпідний синдром.
    Ключові слова антифосфоліпідний синдром,інфаркт міокарда,гострий коронарний синдром,ішемічна хвороба серця,атеросклероз,тромбоз
    Список цитованої літератури
    • Ahmadabad RA, Mirzaasgari Z, Gorji A, Ghadiri MK. Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders International Journal of Molecular Sciences. 2021 Jun; 7;22(11):6153. doi: 10.3390/ijms22116153.
    • Aiello A, Sarti L, Sandri G, Poli D, Sivera P, Barcellona D, et al. Impact of the 2023 ACR/EULAR Classification Criteria on START2 Antiphospholipid Registry. International Journal of Laboratory Hematology. 2025 Apr;47(2): 313–317. doi:  10.1111/ijlh.14416.
    • Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, Hernandez- Juarez J. The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System. Clinical and Applied Thrombosis/Hemostasis.2022 Mar; 23;28:10760296221088576. doi: 10.1177/
    • Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis & Rheumatology. 2023; 75:1687–1702. doi: 10.1002/art.42624.
    • Bernardi M, Spadafora L, Andaloro S, Piscitelli A, Fornaci G, Intonti C, et al. Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults.Journal of Clinical Medicine. 2024; 13(11):3064. doi.org/10.3390/jcm13113064.
    • Bitsadze V, Yakubova F, Khizroeva J, Lazarchuk A, Salnikova P, Vorobev A, et al. Catastrophic Antiphospholipid Syndrome. International Journal of Molecular Sciences. 2024 Jan; 4;25(1):668. doi: 10.3390/ijms25010668.
    • Bolla E, Tentolouris N, Sfikakis PP, Tektonidou MG. Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: Association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques. Frontiers in Immunology. 2023 Jan; 9:13:1077166. doi: 10.3389/fimmu.2022.1077166.
    • Bucci T, Pastori D, Ames P.R.J. REPLY to “Association Between Plasma Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”. Journal of Thrombosis and Thrombolysis. 2022 May; 53(4):974–975. doi: 10. 1007/s11239-021-02625-x.
    • Capozzi A, Manganelli V, Riitano G, Caissutti D, Longo A, Garofalo T, et al. Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts. Journal of Clinical Medicine. 2023; 12:891. doi: 10.3390/jcm12030891.
    • Cavallo D, Armillotta M, Angeli F, Bergamaschi L, Di Iuorio O, Tattilo FP. Unifying Diagnosis Explaining Multiorgan Clinical Manifestations: The Unique Case of Antiphospholipid Syndrome Leading to MINOCA. Circulation: Cardiovascular Imaging. 2023 Aug; 16(8):e015371. doi: 10. 1161/CIRCIMAGING.123.015371.
    • Chayoua W, Nicolson PLR, Meijers JCM, Kardeby C, Garcia- Quintanilla L, Devreese KMJ, et al. Antiprothrombin Antibodies Induce Platelet Activation: A Possible Explanation for anti-FXa Therapy Failure in Patients with Antiphospholipid Syndrome? Journal of Thrombosis and Haemostasis. 2021; 19:1776-1782. doi:10.1111/jth.15320.
    • Chezel J, Fischer Q, Roland PN, Abtan J, Faille D, Gysel DV. Primary antiphospholipid syndrome revealed by acute myocardial infarction in young adults: a prospective observational study. Thrombosis Research. 2021 Feb; 198:151–153. doi: 10. 1016/j.thromres.2020.12.003.
    • Coletto LA, Gerosa M, Valentini M, Cimaz R, Capora R, Meroni PL. Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction. Autoimmun Reviews. 2022 Mar; 21(3):102990. doi: 10. 1016/j.autrev.2021.102990.
    • Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of antiphospholipid syndrome in the general population. Current Rheumatology Research. 2022; 23(12):85. doi:10.1007/s11926–021– 01038–2.
    • de Carvalho JF, Rodrigues CTM. Primary Antiphospholipid Syndrome with and Without Acute Myocardial Infarction/Angina: A Cross- Sectional Study. Rheumatology and Therapy. 2022 Apr; 9(2):581–588. doi: 10. 1007/s40744–021–00419–4.
    • Demartini ZJ, de Araujo WJB, Marcos C. Lange Sneddon Syndrome Neurology India. 2023 Jul-Aug; 71(4):864–865. doi:  10.4103/0028- 3886.383840.
    • Devreese KMJ, Bertolaccini ML, Branch DW, de Laat B, Erkan D, Favaloro EJ, et al. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant.Antiphospholipid Antibodies Journal of Thrombosis and Haemostasis. 2025 Feb; 23(2):731–744. doi: 10.1016/j.jtha.2024.10.022.
    • Evangelatos G, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Tektonidou MG. Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3 year prospective study. Rheumatology (Oxford). 2022; 61(08);3408–3413. doi: 10.1093/rheumatology/keab882.
    • Faizal A, Yoonus S, Nair SR, Kayakkal S, Jose JV. Primary Antiphospholipid Antibody Syndrome Presenting as Acute Myocardial Infarction. Journal of Invasive Cardiology. 2021 Nov; 33(11):E918. doi: 10.25270/jic/21.00199.
    • Gadi I, Fatima S, Elwakiel A, Nazir S, Mohanad Al-Dabet M, Rana R, et al. Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently. Circulation. Res. 2021: 128;513–529. doi: 10.1161/CIRCRESAHA.120.317219.
    • Gan Y, Zhao Y, Li G, Ye H, Zhou Y, Hou C, et al. Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome. Front in Cardiovascular Medicine. 2022 Jul; 5;9:871011. doi: 10.3389/fcvm.2022.871011.
    • Gaspar P, Sciascia S, Tektonidou MG. Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. Rheumatology (Oxford). 2024 Feb; 6;63(SI):SI24–SI36. doi: 10. 1093/rheumatology/kead571.
    • Gérardin C, Bihan K, Joe JE, Khachatryan H, Gerotziafas G, Fain O, et al. Drug-induced antiphospholipid syndrome: Analysis of the WHO international database. Autoimmunity Reviews. 2022 May; 21(5):103060. doi: 10. 1016/j.autrev.2022.103060.
    • Hubben AK, Bazeley P, Swaidani S, Alarabi A, Kulkarn iPP, Shim YJ, et al. Cytokine Profiling in Antiphospholipid Syndrome Demonstrates Persistent Immune Dysregulation and a Procoagulant Phenotype. Blood. 2023 Nov; 142(1):5400. doi:  10.1182/blood-2023–187962.
    • Jin S, Wu S, Cai B, Luo J. Coronavirus disease 2019 and catastrophic antiphospholipid syndrome: A case report. Medicine (Baltimore). 2025 Mar; 28;104(13):e41790. doi: 10. 1097/MD.0000000000041790.
    • Khamashta M, Hughes GRV. Hughes syndrome: The discovery of the antiphospholipid syndrome. Medicina Clinica (Barc). 2024 Aug; 163(l):1:S1-S3. doi: 10. 1016/j.medcli.2024.04.004.
    • Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: Advances in diagnosis, pathogenesis, and management. BMJ. 2023, 380: e069717. doi: 10.1136/bmj-2021-069717.
    • Kulishov SK, Skrypnyk IM, Maslova GS, Shaposhnyk OA, Kudria IP, Prykhodko NP, Shevchenko TL. Inflammation syndrome with autoimmune component in the patients with acute myocardial infarction: quantum genetic algorithm, neuronet. World of Medicine and Biology. 2024; 1 (87): 90-94. doi: 10.26724/2079–8334–2024–1–87–90–94.
    • Lambert M, Brodovitch A, Mège JL, Bertin D, Bardin N. Biological Markers of High Risk of Thrombotic Recurrence in Patients with Antiphospholipid Syndrome: A Literature Review. Autoimmunity. Reviews. 2024, 23:103585. doi:  10.1016/j.autrev.2024.103585.
    • Mu F, Wang Y, Wu H, You Q, Zhang D. The myocardial infarction-associated transcript 2 inhibits lipid accumulation and promotes cholesterol efflux in oxidized low-density lipoprotein-induced THP-1-derived macrophages via inhibiting mitogen-activated protein kinase signaling and activating the nuclear factor erythroid-related factor 2 signaling pathway. Bioengineered. 2022 Jan; 13(1):407–417. doi: 10. 1080/21655979.2021.2005932.
    • Naoum I, Schliamser JE, Zissman K, Fuks A, Zafrir B. Multimodality imaging in a young patient with antiphospholipid syndrome-related acute myocardial infarction. European Heart Journal – Cardiovascular Imaging. 2024 Aug; 26;25(9):e205. doi:  10. 1093/ehjci/jeae088.
    • Nazarova MS, Stanislavchuk MA, Burdeina LV, Zaichko NV. Antiphospholipid and antineutrophil antibody levels in men with stable coronary heart disease and postinfarction cardiosclerosis and its relationship with the disease manifestation. Wiadomosci Lekarskie. 2020; 73(3), 466–470.187 doi: 10.36740/WLek202003111.
    • Nevras V, Milaras N, Katsioulis C, Sotiriou Z, Tsalamandris S, Gkounti G, et al. Acute Coronary Syndromes in Antiphospholipid Syndrome – above Suspicion: A Systematic Review. Current Problems in Cardioogyl. 2023 Mar; 48(3):101503. doi 10.1016/j.cpcardiol.2022.101503.
    • Panopoulos S, Thomas K, Georgiopoulos G, Boumpas D, Katsiari C, Bertsias G, et al. Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study. Rheumatology (Oxford). 2021 Jan; 5;60(1):170–178. doi: 10. 1093/rheumatology/keaa321.
    • Patsouras M, Alexopoulou E, Foutadakis S, Tsiki E, Karagianni P, Agelopoulos M, et al. Antiphospholipid antibodies induce proinflammatory and procoagulant pathways in endothelial cells. Journal of Translational Autoimmunity. 2023 May; 2;6:100202. doi: 10.1016/j.jtauto.2023.100202.
    • Pons I, Jeréz A, Espinosa G, Rodríguez-Pintó I, Erkan D, Shoenfeld Y, et al. Cardiac involvement in the catastrophic antiphospholipid syndrome (CAPS): Lessons from the “CAPS registry” Seminars in Arthritis and Rheumatism. 2024 Jun; 66:152439. doi: 10. 1016/j.semarthrit.2024.152439.
    • Qi W, Zhao J, Huang C. et al. Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study. Arthritis Research and Therapy. 2022 Jun; 11:24(1):140. doi: 10.1186/s13075–022–02814-w.
    • Ramjas V, Jain A, Lee RDM, Fioni F, Tawfik N, Sandhu O, et al. Unraveling the Association Between Myocardial Infarction of Nonobstructive Coronary Arteries and Antiphospholipid Syndrome. Cureus. 2021 Aug; 8;13(8):e17002. doi: 10.7759/cureus.17002.
    • Richter P, Badescu MC, Rezus C, Ouatu A, Dima N, Popescu D, et al. Antiphospholipid Antibodies as Key Players in Systemic Lupus Erythematosus: The Relationship with Cytokines and Immune Dysregulation. International Journal of Molecular Science. 2024; 25(20):11281. doi:10.3390/ijms252011281.
    • Rostoff P, Drwiła-Stec D, Karwat K, Urbańczyk-Zawadzka M, Nessler J, Konduracka E. Primary antiphospholipid syndrome in a male with myocardial infarction with non-obstructive coronary arteries and a history of stroke. Kardiologia Polska. 2023; 81(2):195–197. doi: 10.33963/KP.a2022.0295.
    • Samuelsson I, Parodis I, Gunnarsson I, Zicker A, Hofman-Bang C, Wallén H. Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study. Lupus Science & Medicin. 2021 Jul; 8(1):e000515. doi: 10. 1136/lupus-2021–000515.
    • Schreiber K, Aguilera S, Amengua lO, Cohen H, Castro D, De Andrade O, et al. Diagnostic, research, and real-life effect of the 2023 EULAR- ACR classification criteria for antiphospholipid syndrome. Lancet Rheumatology. 2025 Mar; 7:S2665-9913(24)00396-5. doi: 10. 1016/S2665- 9913(24)00396–5.
    • Stark K, Massberg S. Interplay between Inflammation and Thrombosis in Cardiovascular Pathology. Nature Reviews Cardiology. 2021 Sep; 18(0):666-682. doi: 10.1038/s41569–021–00552–1.
    • Tektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis. Journal of Autoimmunity. 2022; 128: 102813.
    • Tincani A, Fontana G, Mackworth-Young C. The history of antiphospholipid syndrome. Reumatismo. 2022; 74(4):144–150. doi: 10.4081/reumatismo.2022.1556.
    • Tripodi A, Scalambrino E, Clerici M, Peyvandi F. Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients. Biomedicines. 2023; 11(6):1760. doi: 10.3390/biomedicines11061760.
    • Truglia S, Riitano G, Mancuso S, Recalchi S, Rapino L, Garufi C, et al. Antibody profiles in the mosaic of 'seronegative' APS syndrome.Clinical & Experimental Immunology. 2024 Nov; 12;218(3):275–282. doi: 10. 1093/cei/uxae079.
    • Vasileios P, Tsamos G, Vasdeki D, Kotteas E, Kollias A, Nikas D, et al. Antiphospholipid Syndrome: A Comprehensive Clinical Review. Journal of Clinical Medicine. 2025 Jan; 14(3):733. doi: 10.3390/jcm14030733.
    • Yun Z, Duan L, Liu X, Cai Q, Li C. An Update on the Biologics for the Treatment of Antiphospholipid Syndrome. Frontiers of Immunology. 2023; 14: 1145145.
    • Zahidin MA, Iberahim S, Hassan MN, Zulkafli Z, Mohd Noor NH. Clinical and Laboratory Diagnosis of Antiphospholipid Syndrome: A Review. Cureus. 2024 Jun; 5;16(6):e61713. doi: 10.7759/cureus.61713.
    Публікація статті «Світ Медицини та Біології» №2(92), 2025 рік , 223-231 сторінки, код УДК 616.127-005.8:616.155.2
    DOI 10.26724/2079-8334-2025-2-92-223-231